+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Thyroid Gland Disorders Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2017-2025

  • ID: 4851481
  • Report
  • February 2018
  • Region: Global
  • 173 pages
  • Transparency Market Research
1 of 2

Global Thyroid Gland Disorders Treatment Market: Overview

This report on the thyroid gland disorders treatment market analyzes the current and future scenario of the global market. Increasing incidence of thyroid gland disorders. Government regulations and initiatives for increasing awareness about thyroid gland disorders treatment are the major drivers of the global Thyroid Gland Disorders Treatment Market.

The thyroid gland disorders treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on Disorders, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global thyroid gland disorders treatment market.

Global Thyroid Gland Disorders Treatment Market: Key Segments

Based on Disorders, the market has been segmented into hypothyroidism and hyperthyroidism. The disorders market segments have been analyzed based on available approved treatments for hypothyroidism and hyperthyroidism, cost-effectiveness, and preference for industries. Furthermore, Hypothyroidism is categorized into Levothyroxine and Liothyronine, where hyperthyroidism is categorized into Imidazole and Propacil. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Thyroid Gland Disorders Treatment Market: Regional Outlook

Geographically, the global thyroid gland disorders treatment market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global thyroid gland disorders treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Thyroid Gland Disorders Treatment Market are Merck KGaA, Pfizer, Inc., Takeda Pharmaceutical Company Limited, ALLERGAN, Sanofi S.A., AbbVie Inc.,   Lannett Company, Inc., Aspen, Novartis AG, Mylan N.V., and Others.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Thyroid Gland Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025
3.2. Global Thyroid Gland Disorders Treatment Market: Market Snapshot

4. Market Overview
4.1. Global Thyroid Gland Disorders Treatment Market: Product Overview
4.2. Global Thyroid Gland Disorders Treatment Market: Key Industry Developments

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increasing incidence of thyroid gland disorders
5.2.2. Rise in the number of obese, diabetic, and cardiovascular patients, leading to increased risk of thyroid disorders
5.2.3. Growing number of disease awareness programs in developing regions
5.2.4. Focus on spreading awareness about disorders as well as promotional campaigns
5.2.5. Development of effective combination thyroid disorders drug therapies
5.3. Restraints
5.3.1. Rising customer preference for alternative treatments
5.3.2. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
5.4. Opportunities
5.4.1. Asymptomatic nature of thyroid disorders leading to large pool of undiagnosed patients
5.4.2. Increase in research and development activities
5.5. Global Thyroid Gland Disorders (Hypothyroidism and Hyperthyroidism) Epidemiology
5.6. Global Thyroid Gland Disorders Treatment Market Revenue Forecast
5.7. Global Thyroid Gland Disorders Treatment Market Outlook

6. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
6.1. Introduction
6.2. Key Insights
6.3. Global Thyroid Gland Disorders Treatment Market Analysis, by Disorders
6.3.1. Hypothyroidism
6.3.1.1. Levothyroxine
6.3.1.2. Liothyronine
6.3.2. Hyperthyroidism
6.3.2.1. Imidazole
6.3.2.2. Propacil
6.4. Global Thyroid Gland Disorders Treatment Market Forecast, by Disorders
6.4.1. Hypothyroidism
6.4.1.1. Levothyroxine
6.4.1.2. Liothyronine
6.4.2. Hyperthyroidism
6.4.2.1. Imidazole
6.4.2.2. Propacil
6.5. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
6.5.1. Hypothyroidism
6.5.2. Hyperthyroidism

7. Global Thyroid Gland Disorders Treatment Market Analysis, by Region
7.1. Global Thyroid Gland Disorders Treatment Market Forecast, by Region, 2015-2025
7.1.1. North America
7.1.2. Europe
7.1.3. Asia Pacific
7.1.4. Latin America
7.1.5. Middle East & Africa
7.2. Global Thyroid Gland Disorders Treatment Market Value Share Analysis, by Region
7.3. Global Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Region

8. North America Thyroid Gland Disorders Treatment Market Analysis
8.1. North America Thyroid Gland Disorders Treatment Market Key Findings
8.2. North America Thyroid Gland Disorders Treatment Market Overview
8.3. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
8.3.1. Hypothyroidism
8.3.1.1. Levothyroxine
8.3.1.2. Liothyronine
8.3.2. Hyperthyroidism
8.3.2.1. Imidazole
8.3.2.2. Propacil
8.4. North America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
8.4.1. Hypothyroidism
8.4.2. Hyperthyroidism
8.5. North America Thyroid Gland Disorders Treatment Market Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. North America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
8.6.1. Hypothyroidism
8.6.2. Hyperthyroidism

9. Europe Thyroid Gland Disorders Treatment Market Analysis
9.1. Europe Thyroid Gland Disorders Treatment Market Key Findings
9.2. Europe Thyroid Gland Disorders Treatment Market Overview
9.3. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
9.3.1. Hypothyroidism
9.3.1.1. Levothyroxine
9.3.1.2. Liothyronine
9.3.2. Hyperthyroidism
9.3.2.1. Imidazole
9.3.2.2. Propacil
9.4. Europe Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
9.4.1. Hypothyroidism
9.4.2. Hyperthyroidism
9.5. Europe Thyroid Gland Disorders Treatment Market Forecast, by Country
9.5.1. Germany
9.5.2. U.K.
9.5.3. France
9.5.4. Italy
9.5.5. Spain
9.5.6. Rest of Europe
9.6. Europe Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
9.6.1. Hypothyroidism
9.6.2. Hyperthyroidism

10. Asia Pacific Thyroid Gland Disorders Treatment Market Analysis
10.1. Asia Pacific Thyroid Gland Disorders Treatment Market Key Findings
10.2. Asia Pacific Thyroid Gland Disorders Treatment Market Overview
10.3. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
10.3.1. Hypothyroidism
10.3.1.1. Levothyroxine
10.3.1.2. Liothyronine
10.3.2. Hyperthyroidism
10.3.2.1. Imidazole
10.3.2.2. Propacil
10.4. Asia Pacific Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
10.4.1. Hypothyroidism
10.4.2. Hyperthyroidism
10.5. Asia Pacific Thyroid Gland Disorders Treatment Market Forecast, by Country
10.5.1. China
10.5.2. India
10.5.3. Japan
10.5.4. Australia & New Zealand
10.5.5. Rest of Asia Pacific
10.6. Asia Pacific Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
10.6.1. Hypothyroidism
10.6.2. Hyperthyroidism

11. Latin America Thyroid Gland Disorders Treatment Market Analysis
11.1. Latin America Thyroid Gland Disorders Treatment Market Key Findings
11.2. Latin America Thyroid Gland Disorders Treatment Market Overview
11.3. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
11.3.1. Hypothyroidism
11.3.1.1. Levothyroxine
11.3.1.2. Liothyronine
11.3.2. Hyperthyroidism
11.3.2.1. Imidazole
11.3.2.2. Propacil
11.4. Latin America Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
11.4.1. Hypothyroidism
11.4.2. Hyperthyroidism
11.5. Latin America Thyroid Gland Disorders Treatment Market Forecast, by Country
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of Latin America
11.6. Latin America Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
11.6.1. Hypothyroidism
11.6.2. Hyperthyroidism

12. Middle East & Africa Thyroid Gland Disorders Treatment Market Analysis
12.1. Middle East & Africa Thyroid Gland Disorders Treatment Market Key Findings
12.2. Middle East & Africa Thyroid Gland Disorders Treatment Market Overview
12.3. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
12.3.1. Hypothyroidism
12.3.1.1. Levothyroxine
12.3.1.2. Liothyronine
12.3.2. Hyperthyroidism
12.3.2.1. Imidazole
12.3.2.2. Propacil
12.4. Middle East & Africa Thyroid Gland Disorders Treatment Market Value Share Analysis, by Disorders
12.4.1. Hypothyroidism
12.4.2. Hyperthyroidism
12.5. Middle East & Africa Thyroid Gland Disorders Treatment Market Forecast, by Country
12.5.1. GCC Countries
12.5.2. South Africa
12.5.3. Israel
12.5.4. Rest of Middle East & Africa
12.6. Middle East & Africa Thyroid Gland Disorders Treatment Market Attractiveness Analysis, by Disorders
12.6.1. Hypothyroidism
12.6.2. Hyperthyroidism

13. Competition Landscape
13.1. Global Thyroid Gland Disorders Treatment Market Share Analysis, by Company (2016)
13.2. Company Profiles
13.2.1. Merck KGaA
13.2.1.1. Overview (HQ, Employee Strength, Business Segments)
13.2.1.2. Financials
13.2.1.3. Recent Developments
13.2.1.4. Strategy
13.2.2. Pfizer, Inc.
13.2.2.1. Overview (HQ, Employee Strength, Business Segments)
13.2.2.2. Financials
13.2.2.3. Recent Developments
13.2.2.4. Strategy
13.2.3. Takeda Pharmaceutical Company Limited
13.2.3.1. Overview (HQ, Employee Strength, Business Segments)
13.2.3.2. Financials
13.2.3.3. Recent Developments
13.2.3.4. Strategy
13.2.4. ALLERGAN
13.2.4.1. Overview (HQ, Employee Strength, Business Segments)
13.2.4.2. Financials
13.2.4.3. Recent Developments
13.2.4.4. Strategy
13.2.5. Sanofi S.A.
13.2.5.1. Overview (HQ, Employee Strength, Business Segments)
13.2.5.2. Financials
13.2.5.3. Recent Developments
13.2.5.4. Strategy
13.2.6. AbbVie Inc.
13.2.6.1. Overview (HQ, Employee Strength, Business Segments)
13.2.6.2. Financials
13.2.6.3. Recent Developments
13.2.6.4. Strategy
13.2.7. Lannett Company, Inc.
13.2.7.1. Overview (HQ, Employee Strength, Business Segments)
13.2.7.2. Financials
13.2.7.3. Recent Developments
13.2.7.4. Strategy
13.2.8. Aspen
13.2.8.1. Overview (HQ, Employee Strength, Business Segments)
13.2.8.2. Financials
13.2.8.3. Recent Developments
13.2.8.4. Strategy
13.2.9. Novartis AG
13.2.9.1. Overview (HQ, Employee Strength, Business Segments)
13.2.9.2. Financials
13.2.9.3. Recent Developments
13.2.9.4. Strategy
13.2.10. Mylan N.V.
13.2.10.1. Overview (HQ, Employee Strength, Business Segments)
13.2.10.2. Financials
13.2.10.3. Recent Developments
13.2.10.4. Strategy
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll